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PSC: Protect and Serve with
Colitis: does it help the liver to
have severe ulcerative colitis?
Christian Rust, Stephan Brand
Primary sclerosing cholangitis (PSC) is
a rare chronic cholestatic disease of
unknown aetiology affecting the biliary
tree. It is characterised by bile duct
inflammation and fibrosis, and in many
patients it progresses to biliary cirrhosis
and hepatic failure necessitating liver
transplantation. A unique feature of PSC is
its strong association with inflammatory
bowel disease (IBD). In fact, at least 70% of
patients with PSC also suffer from IBD,
most commonly ulcerative colitis (UC).
Conversely, only 2.5e7.5% of patients
with IBD will develop PSC. Although this
association has been known since 1965,1
the underlying pathophysiology is still
unknown. Despite this lack of funda-
mental information, hepatologists in clin-
ical day-to-day business often note that
patients with PSC are seldom troubled
by severe UC. Are these just individual
observations or does a common scheme
exist?
Surprisingly, there are only a few
studies addressing this issue. Patients with
PSC with IBD seem to have a higher
prevalence of pancolitis with rectal
sparing and back-wash ileitis.2 In this
study, a lower rate of colectomies was
noted in patients with PSC/UC as
compared with patients with UC,
suggesting a milder course of colitis in the
PSC/UC group. Indeed, UC may have
a long subclinical course in patients with
PSC, as shown in a small Swedish cohort.3
Two caseecontrol studies also suggest
that UC runs a milder course in patients
with PSC than in those without this liver
disease.4 5 However, a possible association
between the severity of PSC and the
severity of UC has not been studied so far.
In their paper published in this issue of
Gut, Marelli and co-workers (see page
1224) fill this gap with a single-centre
study following 96 patients with PSC/UC
over a long median follow-up period of
12 years.6 These patients were divided
into two groups according to PSC disease
severity. This distinction was made using
the need for liver transplantation (LT)
during the follow-up period as a single,
robust discriminatory parameter. Patients
requiring LT (indicative of a clinically
progressive PSC) had significantly less UC
activity than those without LT. Moreover,
the LT group needed fewer steroids or
azathioprine for UC and had histologically
significantly milder disease. Of note, none
of the LT patients developed high grade
dysplasia or colorectal cancer compared
with 15% in the group without LT,
although a bias might exist since the
patients in the LT group were significantly
younger. Thus, an inverse relationship
between PSC and UC was revealed: mild
UC associated with more severe PSC and,
conversely, active UC associated with less
progressive PSC. How can these inter-
esting results be explained?
Again, little is known to enable this
question to be answered. It would be
interesting to know if IBD activity
changes after the diseased liver is removed
by LT. According to the data of Marelli
et al, UC activity should worsen, although
the situation after LT is more complex.
Several studies showed more exacerba-
tions of IBD after LT despite immuno-
suppressive maintenance treatment which
has a beneficial effect on UC. This trend
was also confirmed in the most recent
study addressing this problem.7 Fifty-nine
patients with PSC were followed for up to
68 months after LT, and the course of IBD
either remained stable or worsened.
Interestingly, 29% of patients without
a pretransplant diagnosis of IBD devel-
oped de novo disease after LT, which is
also consistent with the results of Marelli
et al.6
The underlying mechanisms cannot be
explained satisfactorily at the moment,
but some speculations are possible.
Immune mechanisms play an important
role in the pathogenesis of both PSC and
UC. A number of associations have been
made with HLA (human leucocyte
antigen) haplotypes as well as non-HLA
genes in patients with PSC, supporting an
autoreactive component in PSC patho-
genesis.8 So far, only five of 47 established
UC risk loci have also been replicated in
PSC, suggesting a limited genetic overlap
between both diseases.9e12 Among these
shared risk loci, IL2/IL21, MST1 and
CARD9 represent interesting candidate
genes for PSC and UC.
Interleukin 2 (IL-2) and IL-21 are
important mediators of Tcell development
and seem to have opposing functions
in immunity, with IL-21 predominantly
mediating T helper 17 (Th17) cell-induced
autoimmunity, while IL-2 has protective
functions. For example, Il2ra/ mice
spontaneously develop both intestinal and
biliary inflammation.13 Defective IL-2
expression has also been shown in liver-
derived T cells from patients with PSC.14
Given the overlapping expression of endo-
thelial adhesion molecules and tissue-
specific chemokines between the liver and
the intestine,15 Marelli et al suggest that
severe PSC with decreased liver function
may also depress T cell function and
therefore prevent Tcell-mediated intestinal
inflammation.6
Given the limited shared genetic back-
ground of PSC and UC, other factors such
as bacterial antigens have been suggested
to contribute to the pathogenesis of
these diseases. Many pathogens affect
the intestine as well as the liver (and the
biliary tract). It has been hypothesised
that colonic bacteria enter the portal
circulation through a leaky mucosa in
IBD, thereby causing PSC.16 Bacterial
antigens may act as molecular mimics in
genetically susceptible people and cause an
immune reaction responsible for initiating
PSC. However, this does not explain why
there are fewer patients with PSC with
Crohn’s colitis, which is characterised by
transmural inflammation, as compared
with UC in which inflammation is limited
mostly to the mucosa. There is ample
evidence since the 1970s that cell-medi-
ated and humoral immunity is impaired in
patients with liver cirrhosis.17 So maybe it
is the other way around: in PSC-associ-
ated liver cirrhosis the immunological
attack against the colonic mucosa
responsible for UC is blunted, resulting in
less active colonic disease. In line with this
hypothesis, re-establishment of the liver-
associated immune system by LT could
lead to more active UC despite the use of
immune-suppressive drugs as has been
shown.7
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In conclusion, the paper by Marelli and
co-workers provides important clinical
insight into the interaction of PSC and
UC. Since this was a single-centre study, it
is worthwhile for these findings to be
reproduced by others to exclude a poten-
tial bias. If reproduced, future research
should be directed to unravel the under-
lying mechanisms, which should help to
understand not only the interaction
between UC and PSC but also the still
enigmatic pathophysiology of PSC itself.
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Benefits of bariatric surgery: an
issue of microbialehost
metabolism interactions?
Patrice D Cani, Nathalie M Delzenne
Obesity and type 2 diabetes are becoming
worldwide epidemics. In this regard, the
literature provides evidence that low-grade
inflammation contributes to the onset of
the metabolic disorders associated with
overweight and obesity (insulin resistance,
type 2 diabetes, cardiovascular diseases).1
A considerable number of factors have
been associated with the development of
obesity, including the gut microbiota. The
novel concept, that we defined as
‘MicrObesity ’ (Microbes and Obesity), is
devoted to delineating the impact of
dysbiosis (changes in gut microbiota
composition and/or activity) and its
implications on host metabolism and
energy storage.2 Although the exact
composition of the gut microbiota is not
known, advances in metagenomic and
metabonomic technologies have recently
begun to unravel our microbial partners
including the symbiotic complexity of the
hostegut microbiota interactions,
reflected by a specific chemical signature
in the different biofluids.3
Over the last years, bariatric surgical
approaches (eg, Roux-en-Y gastric bypass
(RYGB) surgery) have provided interesting
results, not only in achieving and main-
taining appropriate weight loss, but most
importantly by the resolution of type 2
diabetes independently of weight
changes.4 Although the modulation of gut
peptides (glucagon-like peptide-1 and
peptide YY (PYY)) has been shown to
contribute to the improvement of diabetes
and appetite sensations, these specific
modifications do not explain per se all the
metabolic changes associated with these
surgical interventions.
In their paper published in this issue of
Gut (see page 1214), Li et al have charac-
terised the metabolic impact of RYGB in
rats, through a 1H nuclear magnetic reso-
nance (1H NMR) spectroscopy-based
metabonomic approach, in combination
with culture-independent technology (454
pyrosequencing) to characterise the gut
microbiota.5 Among the key findings, the
authors have demonstrated an important
increase inProteobacteria (52-fold) anda fall
in levels of Firmicutes (4.5-fold). Although
the increase in Proteobacteria (g-proteo-
bacteria) has been reported previously in
obese human subjects undergoing RYGB
surgery,6 this work further demonstrates
that the main contributor to this change
was Enterobacter hormaecheiwhich increased
byw200- and 43-fold atweeks 2 and8 post-
RYGB surgery. Importantly, the study of Li
et al was performed in non-obese rats. One
would expect to find major differences
between the lean and obese situation
regarding the metabolic and the gut micro-
biota profiles following RYGB surgical
intervention. However, a similar pattern
(increase in Proteobacteria) was observed in
the study of Zhang et al, performed in obese
human subjects, and the experimental
study of Liu et al performed in non-obese
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